NCT03657966 is a Phase 2 clinical trial of DCVAC/OvCa in Ovarian Cancer Recurrent, sponsored by SOTIO a.s..

Who is sponsoring NCT03657966?

NCT03657966 is sponsored by SOTIO a.s..

What drugs are being tested in NCT03657966?

Interventions in NCT03657966: DCVAC/OvCa, Standard of Care Chemotherapy.

What condition does NCT03657966 study?

NCT03657966 studies Ovarian Cancer Recurrent.

Is NCT03657966 still recruiting?

NCT03657966 is currently completed. Last updated 21 April 2021.

Last reviewed 2021-04-21 · How we verify

NCT03657966

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

Completed Phase 2 Last updated 21 April 2021

What this trial tests

Phase 2 trial testing DCVAC/OvCa in Ovarian Cancer Recurrent in 33 participants. Completed in 25 February 2021.

Timeline

23 November 2017

Primary endpoint
11 November 2020

25 February 2021

Quick facts

Lead sponsor	SOTIO a.s.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	23 November 2017
Primary completion	11 November 2020
Estimated completion	25 February 2021
Sites	8 locations across Czechia

Drugs / interventions tested

DCVAC/OvCa — full drug profile →
Standard of Care Chemotherapy — full drug profile →

Conditions studied

Ovarian Cancer Recurrent — all drugs for Ovarian Cancer Recurrent →

Sponsor

SOTIO a.s. — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial ovarian carcinoma who experienced relapse more than 6 months after complete remission of first line platinum-based chemotherapy (platinum sensitive ovarian cancer)

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Yang C, Xia BR, Zhang ZC, Zhang YJ, et al · · 2020 · cited 246× · PMID 33123161 · DOI 10.3389/fimmu.2020.577869
Trial watch: dendritic cell vaccination for cancer immunotherapy.
Sprooten J, Ceusters J, Coosemans A, Agostinis P, et al · · 2019 · cited 107× · PMID 31646087 · DOI 10.1080/2162402x.2019.1638212
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
Johnson RL, Cummings M, Thangavelu A, Theophilou G, et al · · 2021 · cited 33× · PMID 34944851 · DOI 10.3390/cancers13246231
Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment.
Rückert M, Deloch L, Frey B, Schlücker E, et al · · 2021 · cited 30× · PMID 33572437 · DOI 10.3390/cancers13040714
Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer.
Caro AA, Deschoemaeker S, Allonsius L, Coosemans A, et al · · 2022 · cited 22× · PMID 36011029 · DOI 10.3390/cancers14164037
New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection.
Espinar-Buitrago M, Muñoz-Fernández MA. · · 2021 · cited 17× · PMID 35058917 · DOI 10.3389/fimmu.2021.719664
Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy.
Qian C, Yang LJ, Cui H. · · 2020 · cited 16× · PMID 32694998 · DOI 10.3389/fphar.2020.00960

Verify or expand the search:

Other trials of DCVAC/OvCa

Trials testing the same drug.

NCT04834544 — A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care · Phase 2 · recruiting

Other recruiting trials for Ovarian Cancer Recurrent

Currently open trials in the same condition.

NCT07030907 — A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer · Phase 1 · recruiting
NCT06843447 — A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · Phase 1, PHASE2 · recruiting
NCT06791460 — Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer · Phase 2, PHASE3 · recruiting
NCT06660511 — Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Tr · EARLY_PHASE1 · recruiting
NCT05990192 — SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy · Phase 2 · recruiting

Other SOTIO a.s. trials

Trials by the same sponsor.

NCT03514836 — A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Canc · Phase 1, PHASE2 · terminated
NCT02111577 — Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03657966 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SOTIO a.s.
Last refreshed: 21 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03657966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing